XML 38 R26.htm IDEA: XBRL DOCUMENT v3.25.3
Organization and Summary of Significant Accounting Policies (Details Narrative)
3 Months Ended 9 Months Ended 12 Months Ended
Aug. 01, 2025
$ / shares
shares
Jul. 30, 2025
USD ($)
$ / shares
Nov. 16, 2024
USD ($)
Mar. 08, 2024
USD ($)
$ / shares
Sep. 30, 2025
USD ($)
$ / shares
shares
Sep. 30, 2024
USD ($)
shares
Jun. 30, 2024
USD ($)
shares
Sep. 30, 2025
USD ($)
$ / shares
shares
Sep. 30, 2024
USD ($)
shares
Dec. 31, 2024
USD ($)
$ / shares
shares
Sep. 15, 2025
USD ($)
Mar. 20, 2025
USD ($)
Oct. 04, 2024
$ / shares
AccountingPoliciesLineItems [Line Items]                          
Convertible notes                     $ 1,000,000    
Common stock, par value | $ / shares         $ 0.001     $ 0.001   $ 0.001      
Conversion of convertible notes           $ 200,000 $ 400,000            
Conversion of convertible notes, shares | shares                 335,195        
Proceeds from issuance initial public offering               $ 4,940,696        
Cash and cash equivalents and investment securities         $ 10,400,000     10,400,000   $ 9,300,000      
Revenue from Contract with Customer, Excluding Assessed Tax         1,164,617 $ 1,957,500   2,524,819 $ 2,678,013        
Accounts receivable         916,574     916,574   237,027      
Deferred tax assets         $ 19,200,000     $ 19,200,000   $ 17,600,000      
Deferred tax assets valuation allowance coverage percent         100.00%     100.00%   100.00%      
Anti-dilutive securities | shares         6,299,353 5,962,960   6,299,353 5,962,960        
Unvested Restricted Stock Units [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Anti-dilutive securities | shares         64,656 117,925   64,656 117,925        
Common Stock [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Anti-dilutive securities | shares         5,932,097 5,845,035   5,932,097 5,845,035        
Warrant [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Anti-dilutive securities | shares         302,600     302,600          
Six Customers [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Concentration risk number of customers         6                
Ten Customers [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Concentration risk number of customers           10              
Ten Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Concentration risk number of customers               10          
Sixteen Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Concentration risk number of customers                 16        
Three Customers [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Revenue from Contract with Customer, Excluding Assessed Tax         $ 968,138     $ 1,794,521          
Concentration risk percentage         73.00%     67.40%          
Three Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] | Non-US [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Concentration risk percentage               67.20%          
Accounts receivable         $ 616,296     $ 616,296          
Two Customers [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Revenue from Contract with Customer, Excluding Assessed Tax           $ 1,357,584   $ 1,449,944          
Concentration risk percentage           69.40%   54.10%          
Five Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Revenue from Contract with Customer, Excluding Assessed Tax               $ 878,115          
Concentration risk percentage               95.80%          
Nine Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Revenue from Contract with Customer, Excluding Assessed Tax                   $ 158,416      
Concentration risk percentage               66.90%          
Three Customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Non-US [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Revenue from Contract with Customer, Excluding Assessed Tax         $ 447,688     $ 677,126          
Concentration risk percentage         38.40%     26.80%          
Four Customers [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Non-US [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Revenue from Contract with Customer, Excluding Assessed Tax           $ 549,528              
Concentration risk percentage           28.10%              
Four Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] | Non-US [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Concentration risk percentage                   61.50%      
Accounts receivable                   $ 145,603      
Eight Customers [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Non-US [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Revenue from Contract with Customer, Excluding Assessed Tax                 $ 853,530        
Concentration risk percentage                 31.90%        
One CROs [Member] | Contract Research Organizations [Member] | Supplier Concentration Risk [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Concentration risk percentage         87.20% 94.60%              
Research services purchased         $ 991,069 $ 690,359              
Two CROs [Member] | Contract Research Organizations [Member] | Supplier Concentration Risk [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Concentration risk percentage               87.60% 92.00%        
Research services purchased               $ 2,385,116 $ 1,647,399        
Two CROs [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Concentration risk percentage                   58.90%      
Accounts payable         684,503     684,503   $ 284,166      
Gates Foundation [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Proceeds from grants     $ 3,092,136                    
Revenue from Contract with Customer, Excluding Assessed Tax         527,363     1,065,470          
CEPI [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Grant receivable                       $ 2,400,000  
Revenue from Contract with Customer, Excluding Assessed Tax         287,209     462,754          
Accounts receivable         $ 462,754     462,754          
CEPI [Member] | Fondazione Biotecnopolo Di Siena Fbs [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Grant receivable                       $ 4,500,000  
Common Stock [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Conversion of convertible notes           $ 111 $ 223     $ 910,000      
Conversion of convertible notes, shares | shares           111,732 223,463     556,623      
Shares issued | shares 6,052,000       6,052,000                
Public offering price, per share | $ / shares $ 0.95 $ 0.95                      
Proceeds from issuance initial public offering   $ 4,900,000                      
Senior Secured Convertible Promissory Notes [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Convertible notes       $ 6,000,000.0                  
Interest rate       8.00%                  
Common stock, par value | $ / shares       $ 0.001                  
Proceeds from sale of convertible notes       $ 5,824,326                  
Debt instrument convertible conversion price | $ / shares                         $ 1.40
Mark A Emalfarb Trust [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Convertible notes [1]         $ 1,000,000     $ 1,000,000          
Interest rate [1]         8.00%     8.00%          
Mark A Emalfarb Trust [Member] | Mr Mark A Emalfarb [Member]                          
AccountingPoliciesLineItems [Line Items]                          
Convertible notes                     $ 1,000,000    
Accrued interest amount         $ 3,334     $ 3,334          
[1] On September 15, 2025, Mark A. Emalfarb Trust dated October 1, 1987, as amended and restated on June 28, 2019 (the “MAE Trust”), purchased and was assigned $1,000,000 of the Convertible Notes from an existing note holder. Mr. Mark A. Emalfarb, our Chief Executive Officer, is the sole beneficiary and serves as sole trustee of the MAE Trust and has sole voting and dispositive power over the shares of Common Stock held by the MAE Trust. As of September 30, 2025, the amount of accrued interest for the MAE Trust was $3,334.